Rosiglitazone
-
Subject Areas on Research
- Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia.
- Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
- Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
- Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
- Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.
- Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone.
- Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy.
- Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
- Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
- Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons.
- Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
- Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
- The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
- The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone.
- Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells.